meningococcus

(redirected from Neisseria meningitidis)
Also found in: Medical, Acronyms, Encyclopedia, Wikipedia.
Related to Neisseria meningitidis: Neisseria gonorrhoeae

me·nin·go·coc·cus

 (mə-nĭng′gə-kŏk′əs, -nĭn′jə-)
n. pl. me·nin·go·coc·ci (-kŏk′sī, -kī)
A bacterium (Neisseria meningitidis) that causes cerebrospinal meningitis.

me·nin′go·coc′cal (-kŏk′əl), me·nin′go·coc′cic (-kŏk′sĭk) adj.

meningococcus

(mɛˌnɪŋɡəʊˈkɒkəs)
n, pl -cocci (-ˈkɒkaɪ)
(Medicine) the bacterium that causes cerebrospinal meningitis

me•nin•go•coc•cus

(məˌnɪŋ goʊˈkɒk əs)

n., pl. -coc•ci (-ˈkɒk saɪ, -si)
a spherical or kidney-shaped bacterium, Neisseria meningitidis, that causes cerebrospinal meningitis.
[1890–95; < New Latin]
me•nin`go•coc′cal, me•nin`go•coc′cic (-ˈkɒk ɪk, -ˈkɒk sɪk) adj.
Translations

me·nin·go·coc·cus

n. meningococo, uno de los microorganismos causantes de la meningitis cerebral epidémica.

meningococcus

n (pl -ci) meningococo
Mentioned in ?
References in periodicals archive ?
Meningococcal septicemia results from Neisseria meningitidis infection and leads to the rapid development of severe septic shock.
Temporal changes in BEXSERO[R] antigen sequence type associated with genetic lineages of Neisseria meningitidis over a 15-year period in Western Australia.
Although there are vaccines for several Neisseria meningitidis strains, the B strain caused particular difficulty for scientists.
4 Adolescents remain a very important group for vaccination, as up to a quarter may be asymptomatic carriers of Neisseria meningitidis.
This report provides comprehensive information on the therapeutic development for Neisseria Meningitidis Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
This Ministry was established to regulate the system of public health surveillance focused on bacterial meningitis, especially those caused by Neisseria meningitidis, Haemophilus influenzae, and Streptococcus pneumoniae.
Science company Pfizer (NYSE:PFE) said on Thursday that it has filed its Biologics License Application (BLA) with the US Food and Drug Administration (FDA) for review for its vaccine candidate for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B.
MenACWY-CRM prevents invasive meningococcal disease that is caused by Neisseria meningitidis serogroups A, C, Y, and W- 135.
specific strains of Neisseria meningitidis have become resistant to the sulfonamides usually used for treatment or prevention.
Din, 25, a meningitis research associate at the San Francisco Veterans Affairs Medical Center, was part of a team working to develop a vaccine for Neisseria meningitidis.